You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

What Has New Research Identified in Low-Risk Melanoma?

  • Authors: News Author: Roxanne Nelson, RN, BSN; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 1/27/2023
  • Valid for credit through: 1/27/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, dermatologists, internists, nurses, family medicine/primary care clinicians, physician assistants, and other members of the health care team caring for patients with low-risk melanoma.

The goal of this activity is for learners to be better able to describe subsets of patients with melanoma with very low risk for death, based on an analysis of classification and regression tree and logistic regression models, using data from the US Surveillance, Epidemiology, and End Results database.

Upon completion of this activity, participants will:

  • Assess subsets of patients with melanoma with very low risk for death, based on an analysis of classification and regression tree and logistic regression models, using Surveillance, Epidemiology, and End Results data
  • Evaluate the clinical implications of subsets of patients with melanoma with very low risk for death, based on an analysis of classification and regression tree and logistic regression models, using Surveillance, Epidemiology, and End Results data
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Roxanne Nelson, RN, BSN

    Freelance writer, Medscape

    Disclosures

    Roxanne Nelson, RN, BSN, has no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Laurie Barclay, MD, has the following relevant financial relationships:
    Formerly owned stocks in: AbbVie Inc.

Editor/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 01/27/2024. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

What Has New Research Identified in Low-Risk Melanoma?

Authors: News Author: Roxanne Nelson, RN, BSN; CME Author: Laurie Barclay, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 1/27/2023

Valid for credit through: 1/27/2024, 11:59 PM EST

processing....

Clinical Context

Melanoma is the most prevalent potentially fatal skin cancer, but prognosis is very good for American Joint Committee on Cancer (AJCC) stage T1 disease. Prognostic modeling can predict survival in patients with melanoma and identify prognostic variables.

AJCC staging uses Breslow thickness and primary tumor ulceration. Mitotic rate, Clark levels of invasion III and greater, and tumorigenicity or vertical growth phase also strongly correlate with poorer outcomes.

Study Synopsis and Perspective

Although melanoma is the most serious skin cancer, most patients do have high chances of survival. New research has now identified a subset of patients with early disease who have a very low risk of dying from the disease.

In a cohort of almost 11,600 patients, the overall 7-year rate of death from melanoma was 2.5%, but the risk in a subset of 25% of patients was below 1%.

Conversely, the study authors were also able to identify a small subset of high‐risk patients with a greater than 20% risk for death.

Although more data are needed and the findings should be verified in other studies, the use of a different term such as “melanocytic neoplasms of low malignant potential,” rather than “melanoma,” may be more appropriate and may help to begin to address the problem of overdiagnosis, the authors note.

“While the topic of very low risk melanomas has been presented at national and international meetings, there have been no formal discussions to define the classification of ‘melanocytic neoplasms of low malignant potential’ at this time,” first author Megan M. Eguchi, MPH, from the Department of Medicine, University of California, Los Angeles, said in an interview. “Criteria would need to be established using study designs beyond those available using [Surveillance, Epidemiology, and End Results (SEER)] data.”

She emphasized that at this time, they do not propose any change to treatment of these lesions, just a change to the terminology.

The study was recently published online in Cancer.

Even though melanoma is considered to be the most common potentially lethal tumor of the skin, prognosis is often very good for those with T1 tumors--those in the lowest risk category. Prognostic modeling has been used to predict survival in patients with melanoma and to identify prognostic variables, the authors note, with the most prominent attributes being Breslow thickness and ulceration of the primary tumor, which form the basis of the current AJCC staging system.

There is evidence that the increasing incidence of melanoma is partly a result of overdiagnosis, meaning the diagnosis of lesions that will not lead to symptoms or death. The authors write that they were interested in identifying lesions that are currently diagnosed as melanoma but might lack the capacity for metastasis--cases that could potentially be part of the phenomenon of overdiagnosis.

Subsets With Low and High Risk for Death

In the study, Dr Eguchi and colleagues analyzed information from the SEER database and identified 11,594 patients who were diagnosed in 2010 and 2011 with stage 1 melanoma that was 1.0 mm in thickness or smaller and had not spread to the lymph nodes. Prognostic models for risk for death from melanoma in patients with low-risk melanomas were developed, and then the ability of the models to identify very low risk subsets of patients with melanoma‐specific survival surpassing that of T1 overall was evaluated.

The median age of the patients was 58 years, the median Breslow thickness was 0.45 mm (interquartile range [IQR], 0.30-0.65 mm), and 71% were assigned stage IA. Ulceration was present in 4% of cases, 27% were mitogenic, and 45% were Clark level II, and within this cohort, 292 (2.5%) patients died of melanoma within 7 years. In the training data set, 177 (2.3%) of 7652 patients died of melanoma within 7 years; numbers were similar in the testing set (115 of 3942; 2.9%).

Overall, the investigators identified 3 large subsets of patients who were in the AJCC 7th edition classification for stage I (“thin”) melanoma, who had a risk for death of approximately less than 1%. This was a marked improvement from the rate of the overall sample. In the simplest model (model 1A), patients who were younger than 70 years at diagnosis with Clark level II invasion were deemed at very low risk.

In model 1B the same initial classification was used, but it was further refined and limited to patients who were either aged 43 years or younger or aged 44 to 69 years with Breslow thickness less than 0.40 mm. At 10 years postdiagnosis this subset also showed a less than 1% risk for death from melanoma. The logistic regression model (model 2) was similar, as it identified about 25% of patients with a predicted risk for death of less than 0.5%, incorporating patient age, sex, mitogenicity, Clark level, and ulceration. Model 2 was also able to further identify a small subset of patients with no deaths.

The logistic regression model was also able to identify a very small subset (0.7% and 0.8%) of patients who had a risk for death that exceeded 20%, which was markedly higher compared with that of most patients with T1b tumors.

More Data Needed

Commenting on the study, Beth Goldstein MD, a dermatologist and cofounder of Modern Ritual Health, Chapel Hill, North Carolina, noted that in the future, when there is the ability to determine which lesions have an aggressive biologic potential, “then ideally, we can avoid unnecessary removals.”

Dr Goldstein acknowledged that there are unnecessary procedures performed perhaps for lesions that would never become life threatening, but at the same time, it is known that there are certain early lesions that are more likely to metastasize and are only known after a complete removal and pathologic assessment. 

In addition, besides concerns with removing a suspicious lesion, such as scarring, “there is very limited morbidity associated with this procedure,” she said. “Most patients with early melanomas do not require more than an outpatient procedure under local anesthetic and are already reassured of the low-risk nature of their early melanoma.”

At this time, “we do not have the ability to differentiate these tumors further from the initial assessment,” Dr Goldstein continued. “While there is an ability to screen melanomas for higher likelihood for metastasis with the 31 genetic expression profile test, there is still much work to be done to refine these resources.”

This study was supported by National Cancer Institute. Dr Eguchi and Dr Goldstein have disclosed no relevant financial relationships.

Cancer. November 7, 2022.[1]

Study Highlights

  • Using the SEER database, 11,594 melanoma patients diagnosed in 2010 to 2011 with stage I lesions 1.0 mm thick or less and negative clinical lymph nodes were selected.
  • Median patient age was 58 years, median Breslow thickness 0.45 mm (IQR, 0.30-0.65 mm), 71% were stage IA, 4% had ulceration, 27% were mitogenic, and 45% were Clark level II; 2.5% died of melanoma within 7 years.
  • Classification and regression tree and logistic regression models were developed and validated to identify patients with very low risk for melanoma death within 7 years.
  • Logistic models were also used to identify patients at higher mortality risk among this group of stage I patients.
  • Melanoma death within 7 years occurred in 2.3% of the training data set and 2.9% of the testing set.
  • In all models, factors associated with lower mortality were younger age at diagnosis, Clark level II, Breslow thickness less than 0.4 mm, lack of mitogenicity or of ulceration, and female sex.
  • Three large subsets of patients were in the AJCC 7th edition classification for stage I (“thin”) melanoma, with mortality risk approximately less than 1%.
  • In the simplest model (1A), patients younger than 70 years at diagnosis with Clark level II invasion (35% of patients) were deemed to be at very low risk for death (0.58%; 95% CI, 0.29%-1.14%).
  • In model 1B, patients with Clark level II who were aged 43 years or younger or aged 44 to 69 years with Breslow thickness less than 0.40 mm (25% of patients) had 0.40% (95% CI, 0.16%-1.03%) risk for melanoma death at 10 years postdiagnosis.
  • Neither model 1A nor model 1B incorporated mitogenicity.
  • The logistic regression model (model 2) incorporating age, sex, mitogenicity, Clark level, and ulceration identified approximately 25% of patients with predicted mortality risk less than 0.5%, a small subset of patients with no deaths, and 0.7% to 0.8% of patients with mortality risk higher than 20%, which was markedly higher than in most T1b tumors.
  • The investigators concluded that their models identified patients with very low risk for melanoma death within 7 years of diagnosis, warranting further study and consensus discussion to develop classification criteria, with the potential for categorization using an alternative term such as MNLMP.
  • Age and Clark level were essential factors in all models, but Breslow thickness was not significantly associated with survival at 7 years, nor included in the final model.
  • To avoid unnecessary removals, further research is needed to identify lesions with aggressive biologic potential.
  • A small number of patients classified as stage I may be at sufficiently high risk (>20% within 7 years) to potentially consider more aggressive treatment.

Clinical Implications

  • Prognostic models identified patients with very low risk for melanoma death within 7 years of diagnosis. A small number of patients classified as stage I may be at sufficiently high risk to potentially consider more aggressive treatment.
  • This warrants further study and consensus discussion to develop classification criteria, as well as potential use of an alternative term (melanocytic neoplasms of low malignant potential).
  • Implications for the Health Care Team: As new data emerges about very low-risk melanomas, members of the healthcare team should advise patients that removal remains recommended and that there is very limited morbidity associated with the procedure as it is done in an outpatient setting under local anesthetic.

 

Earn Credit

  • Print